CME Group Inc (CHME34)
Sao Paulo Exchange · Brazil · prices in BRL · close of 23 Oct 2026
Key indicators
| Last close | BRL 77.10 |
|---|---|
| 52-week range | 57.88 – 86.02 |
| Return, 1 month / 3 months | +9.7% / +21.5% |
| Return, 1 year / 3 years | +19.4% / +119.9% |
| Trend | Uptrend |
| RSI (14) | 77 |
| Volatility (1 year) | 28.0% |
| Worst drawdown (1 year) | -29.1% |
| Average daily value traded | 0.07M BRL |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
CME Group is a derivatives marketplace operator based in Chicago. It runs exchanges that trade futures and options contracts on interest rates, equity indexes, foreign exchange, energy, metals and agricultural commodities. Its customers include financial institutions, trading firms, corporations and other market participants who use these contracts to manage risk and to take positions. The company also provides clearing services for trades and supplies market data and related technology to users of its markets.
CME Group Inc is represented on the Sao Paulo Exchange in Brazil by a Brazilian depositary receipt (BDR) under the code CHME34, with its price quoted in Brazilian reais (BRL). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
CME Group Inc (CHME34) trades on the Sao Paulo Exchange in Brazil. It last closed at BRL 77.10 on 23 October 2026.
Its price-based Market X-Ray is 62 out of 100 (a fair price profile), ranking 365 of 1,454 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 19.4% and over the last three months it rose 21.5%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Sao Paulo Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 66 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 10.9% | ||
| From 52-week high | -10.4% | ||
| Momentum | 69 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 21.5% | ||
| 6-month return | 9.3% | ||
| 12-month return, skipping the last month | 8.8% | ||
| Stability (higher is calmer) | 64 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 28.0% | ||
| Worst drawdown, 1 year (smaller is calmer) | -29.1% | ||
| Liquidity | 38 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.07M BRL | ||
| Zero-volume days | 43.3% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 6 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +7.1% |
|---|---|
| 1 month | +9.7% |
| 3 months | +21.5% |
| 6 months | +9.3% |
| 1 year | +19.4% |
| 3 years | +119.9% |
| 5 years | +173.1% |
Signals
| 50-day / 200-day average | 70.65 / 69.53 |
|---|---|
| Golden / death cross (60 days) | Golden, 12 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.01 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 5 Jun 2026 | USD 5.6816 |
| 6 Mar 2026 | USD 11.4364 |
| 10 Dec 2025 | USD 5.7460 |
| 5 Sep 2025 | USD 5.6480 |
| 5 Jun 2025 | USD 5.8277 |
| 5 Mar 2025 | USD 6.0738 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Sao Paulo Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.